IRulya Therapeutics Inc.
5 private offerings reported to the SEC on Form D since 2016, $226.2M sold in all. Biotech, CA.
- Form D offerings: 5
- Reported sold: $226.2M
- Newest: Jun 11, 2026
Every Form D Offering
Newest first; an amended notice updates the amount sold. Each filing opens on EDGAR.| Jun 11, 2026 | $114.7M | $186.4M | Quince Therapeutics, Inc.Biotech · CA | Not amended | 0000912282-26-000809 |
| Jul 1, 2025 | $11.5M | $21.9M | Quince Therapeutics, Inc.Biotech · CA | Not amended | 0001662774-25-000035 |
| May 31, 2018 | $84.5M | $85.6M | Cortexyme, Inc.Pharma · CA | Not amended | 0001662774-18-000001 |
| Feb 14, 2017 | $7.6M | $8.0M | Cortexyme, Inc.Pharma · CA | Not amended | 0001662774-17-000001 |
| Jan 5, 2016 | $7.9M | $15.9M | Cortexyme, Inc.Pharma · CA | Not amended | 0001662774-16-000002 |
SEC Profile
From the company's EDGAR record- Ticker
- IRLA
- Business address
- New Haven, Ct
- Incorporated in
- DE
- SEC industry
- Biological Products, (No Diagnostic Substances)
- Former names
- Quince Therapeutics, Inc.; Cortexyme, Inc.
- All SEC filings
- CIK 1662774 on EDGAR
A Form D reports the amount offered and sold so far in a private offering, not who invested or at what valuation. Shares issued in a merger are left out. The profile is read from EDGAR daily. SEC Form D data sets and EDGAR